An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox

An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox

Mpox is an acute exanthematous disease caused by the monkeypox virus. Since May 2022, it has spread as a community-acquired infection, mainly in Europe and the United States, and urgent measures to prevent this infection were also required in Japan. In this study, we investigated the post-exposure p...

Full description

Bibliographic Details
Main Authors: Noriko Tomita, Junko Terada-Hirashima, Yukari Uemura, Yosuke Shimizu, Haruka Iwasaki, Rina Yano, Tetsuya Suzuki, Sho Saito, Nobumasa Okumura, Wataru Sugiura, Norio Ohmagari, Mugen Ujiie
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
mpox
smallpox vaccine
mpox vaccine
open-label
non-randomized study
post-exposure prophylaxis
lc16
adverse events
vaccine safety
vaccine efficacy
Online Access:http://dx.doi.org/10.1080/21645515.2023.2242219

Internet

http://dx.doi.org/10.1080/21645515.2023.2242219

Similar Items